Johnson & Johnson posts strong revenue in 1Q

Lower sales overseas and higher costs for research and litigation pushed Johnson & Johnson’s first-quarter profit down 14%. Still, the health care giant beat profit and revenue expectations, pushing up its shares in premarket trading.

The maker of Tylenol and psoriasis drug Stelara on Tuesday said unfavourable currency exchange rates reduced revenue by nearly 4%, leaving total sales flat at $20.03 billion, though that edged out analysts’ muted projections.

Sales of prescription medicines were the bright spot as usual, rising 4% and accounting for over half of the New Brunswick, New Jersey, company’s total revenue.

The segment just got a boost from two U.S. Food and Drug Administration approvals, in March for nasal spray treatment Spravato for adults with treatment-resistant depression and last week for bladder cancer drug Balversa.

Earlier this month, J&J completed a key acquisition, paying $3.4 billion for Auris Health, which makes robotic technology used in lung treatments and diagnostic procedures. Johnson & Johnson said the deal will expand its digital surgery portfolio across multiple surgical specialties. J&J also struck a partnership with MeiraGTx to develop gene therapies for eye diseases.

The world’s biggest maker of health care products posted net income of $3.75 billion, or $1.39 per share, down from $4.37 billion, or $1.60 per share, a year earlier.

Earnings, adjusted for litigation costs and research and development expenses, were $5.66 billion, or $2.10 per share, 7 cents better that Wall Street expected, according to a survey by Zacks Investment Research.

Revenue was $20.02 billion, with $10.24 billion of that coming from its prescription drugs. Sales were led by Stelara, which saw a 32.4% jump to $1.41 billion. Higher sales of cancer drugs Imbruvica and Darzalex, HIV drug Prezista and schizophrenia treatment Invega Sustenna also lifted the results and helped offset lower sales of blockbuster immune treatment Remicade and blood thinner Xarelto.

Sales of consumer health products dipped 2.4% to $3.32 billion, and medical device sales fell 4.6% to $6.46 billion.

The company reaffirmed its January forecast for 2019 sales totalling $80.4 billion to $81.2 billion, but raised the low end of its earnings-per-share forecast 3 cents, giving a new range of $8.53 to $8.63 for the full year.

In premarket trading, J&J shares jumped $2.57, or 1.9%, to $139.09.

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

Oilers 50/50 raffle delayed further as team resolves errors, offers refunds

EDMONTON — A record-setting Edmonton Oilers 50/50 draw won’t have a winner… Continue reading

The latest numbers on COVID-19 in Canada for Aug. 9

The latest numbers of confirmed COVID-19 cases in Canada as of 4:50… Continue reading

Liberals turn over thousands of pages on WE decision, lawyers now vetting docs

OTTAWA — The federal Liberal government has handed over thousands of pages… Continue reading

Samson Cree Nation reeling after 10 year-old-boy-shot, 13-year-old charged with manslaughter

‘Don’t give up, keep praying, we will get through this’

Kamloops boat crash sends 2 passengers to hospital, police investigating

KAMLOOPS, B.C. — Two vessels collided on the South Thompson River Saturday,… Continue reading

QUIZ: Do you know the truth?

In what has been described as a post-truth era, how much do you know about truth and lies?

Cast your votes for Best of Red Deer

The Advocate’s Best of Red Deer Readers’ Choice Awards are back. Community… Continue reading

Sylvan Lake couple donates $850,000 to AACS

The doantion will be put towards a new X-Ray machine for the facility

Call the police if you’re disturbed by noisy vehicles

I’m disgusted at the nightly vehicle noise in Red Deer. Night after… Continue reading

Explosion helps to hasten the meltdown of Lebanon

Beirut has been living with car bombs and air raids on a… Continue reading

Take comfort — it could be hotter

If it’s one thing we humans are pretty good at, it’s complaining… Continue reading

Singer Salome Bey, known as Canada’s first lady of the blues, dies at age 86

Singer Salome Bey, known as Canada’s first lady of the blues, has… Continue reading

US investigates electrical fires in 2014 Chrysler minivans

DETROIT — The U.S. government’s road safety agency is investigating complaints of… Continue reading

Greece slams Turkish announcement on energy research in eastern Med

ATHENS, Greece — Greece on Monday slammed a Turkish announcement that it… Continue reading

Most Read